
Opinion|Videos|August 14, 2024
Monitoring Response in Immune Checkpoint Inhibitor-Based RCC Therapy
Medical experts examine strategies for monitoring treatment response in patients initiating first-line immune checkpoint inhibitor-based therapy for metastatic renal cell carcinoma.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5







































